In 2022, the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) reported that aromatase inhibitors (AI) such as anastrozole, exemestane, or letrozole had a lower recurrence rate than tamoxifen in patients with early premenopausal hormone receptor-positive breast cancer accompanied by ovarian suppression therapy [7]. The gene discussed is NR4A1; the disease is breast cancer.